Vanda Pharmaceuticals (VNDA) Cost of Revenue (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 14 years of Cost of Revenue data on file, last reported at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 10.28% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.7 million (up 11.29% YoY), and the FY2025 full-year result was $13.0 million, up 15.29% from the prior year.
• Cost of Revenue slipped to $3.2 million in Q1 2026, from $3.8 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $6.3 million in Q3 2022 to a low of $2.6 million in Q3 2024.
• A 5-year average of $3.9 million and a median of $3.5 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue sank 51.53% in 2023 and surged 47.99% in 2025, its largest moves.
• Tracing VNDA's Cost of Revenue over 5 years: stood at $6.2 million in 2022, then tumbled by 44.53% to $3.5 million in 2023, then declined by 25.14% to $2.6 million in 2024, then surged by 47.99% to $3.8 million in 2025, then dropped by 17.58% to $3.2 million in 2026.
• Business Quant data shows VNDA's Cost of Revenue at $3.2 million in Q1 2026, $3.8 million in Q4 2025, and $3.0 million in Q3 2025.